Abstract
Canavan disease (CD) is an autosomal recessive disorder, caused by mutations in the aspartoacylase gene resulting enzyme deficiency. Patients with CD have accumulation of NAAG and NAA in the brain resulting elevated urinary NAAG and NAA. Aspartoacylase gene mutation in the mouse led to multiple genomic abnormalities. Pathophysiological processes implicated in CD include spongy degeneration of the brain possibly by the abnormal genes expression / metabolic levels of NAAG, NAA, aspartate, glutamate, glutamate transporter-EAAT4, GABA receptor-GABRA6 and GABA. In addition, high expression of cell death inducing agents includes serine proteinase inhibitor 2, caspase 11 and interleukin 1- beta. Osteoporosis is also an important consequence in the CD mouse. Each of these pathways offers potential therapeutic targets and pharmacological manipulation.
Keywords: canavan disease, ast, glutamate, eaat4, gabra6, gaba
Current Pharmacogenomics
Title: Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Volume: 2 Issue: 1
Author(s): Sankar Surendran, Stephen K. Tyring, Kimberlee Michals-Matalon and Reuben Matalon
Affiliation:
Keywords: canavan disease, ast, glutamate, eaat4, gabra6, gaba
Abstract: Canavan disease (CD) is an autosomal recessive disorder, caused by mutations in the aspartoacylase gene resulting enzyme deficiency. Patients with CD have accumulation of NAAG and NAA in the brain resulting elevated urinary NAAG and NAA. Aspartoacylase gene mutation in the mouse led to multiple genomic abnormalities. Pathophysiological processes implicated in CD include spongy degeneration of the brain possibly by the abnormal genes expression / metabolic levels of NAAG, NAA, aspartate, glutamate, glutamate transporter-EAAT4, GABA receptor-GABRA6 and GABA. In addition, high expression of cell death inducing agents includes serine proteinase inhibitor 2, caspase 11 and interleukin 1- beta. Osteoporosis is also an important consequence in the CD mouse. Each of these pathways offers potential therapeutic targets and pharmacological manipulation.
Export Options
About this article
Cite this article as:
Surendran Sankar, Tyring K. Stephen, Michals-Matalon Kimberlee and Matalon Reuben, Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease, Current Pharmacogenomics 2004; 2 (1) . https://dx.doi.org/10.2174/1570160043476141
DOI https://dx.doi.org/10.2174/1570160043476141 |
Print ISSN 1570-1603 |
Publisher Name Bentham Science Publisher |
Online ISSN 1570-1603 |
Related Articles
-
Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Polymer-based Drug Delivery Systems Applied to Insects Repellents Devices: A Review
Current Drug Delivery Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Current Pharmaceutical Design EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Directing the Antiretroviral Drugs to the Brain Reservoir: A Nanoformulation Approach for NeuroAIDS
Current Drug Metabolism Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Stationary Wavelet Transform and AdaBoost with SVM Based Pathological Brain Detection in MRI Scanning
CNS & Neurological Disorders - Drug Targets Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis
Current Neurovascular Research Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science